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Abstract  35 
 36 
Using two-photon induced fluorescence lifetime imaging microscopy, we corroborate 37 
an interaction (previously demonstrated by yeast two-hybrid domain analysis) of full-38 
length Vaccinia virus (VACV; an orthopoxvirus) A36 protein with the cellular 39 
microtubule motor protein, kinesin. Quenching of enhanced green fluorescent protein 40 
(EGFP), fused to the C-terminus of VACV A36, by monomeric red fluorescent 41 
protein (mDsRed), fused to the tetratricopeptide repeat (TPR) domain of kinesin, was 42 
observed in live chicken embryo fibroblasts (CEFs) infected with either Modified 43 
Vaccinia virus Ankara (MVA) or wild-type Fowlpox virus (FWPV; an avipoxvirus), 44 
the excited state fluorescence lifetime of EGFP being reduced from 2.5 + 0.1 ns to 2.1 45 
+ 0.1 ns due to resonance energy transfer to mDsRed. FWPV does not encode an 46 
equivalent of intracellular enveloped virion surface protein A36 yet it is likely this 47 
virus too must interact with kinesin to facilitate intracellular virion transport. To 48 
investigate possible interactions between innate FWPV proteins and kinesin, 49 
recombinant FWPVs expressing EGFP fused to the N-termini of FWPV structural 50 
 3 
proteins Fpv140, Fpv168, Fpv191 and Fpv198 (equivalent to VACV H3, A4, p4c and 51 
A34, respectively) were generated. EGFP fusions of intracellular mature virion (IMV) 52 
surface protein Fpv140 and type II membrane protein Fpv198 were quenched by 53 
mDsRed-TPR in rFWPV-infected cells, indicating that these virion proteins are found 54 
within 10 nm of mDsRed-TPR. In contrast, and as expected, EGFP fusions of the 55 
IMV core protein Fpv168 did not show any quenching. Interestingly, the p4c-like 56 
protein Fpv191, which demonstrates late association with pre-assembled IMV, also 57 
did not show any quenching.  58 
 59 
Introduction 60 
 61 
Viruses, including the best-studied and prototypic poxvirus, Vaccinia virus (VACV), 62 
lack intrinsic motility. During the early stages of infection, VACV exploits the 63 
microtubule cytoskeleton and the dynein-dynactin complex to permit delivery of 64 
infecting virions to the site of future replication (34). Later in the infection, it disrupts 65 
microtubule organisation, centrosome function and actin organisation, and 66 
polymerises actin beneath membrane-bound, enveloped virus particles to assist 67 
dispersal (11). During morphogenesis, various different types of VACV particles are 68 
observed within the infected cell: immature virions (IV), intracellular mature virus 69 
(IMV, also known as mature virions, MV), intracellular enveloped virus (IEV, also 70 
known as wrapped virions, WV), cell-associated enveloped virus (CEV), and 71 
extracellular enveloped virus (EEV), the last two also being known collectively as 72 
extracellular virions (EV) (9, 32, 37, 46). These particles display different VACV 73 
proteins on their surfaces, dependent primarily on the nature and origins of the 74 
particular outer membrane that surrounds the nucleic acid-containing core.  75 
 4 
 76 
VACV surface proteins, both IMV-specific (A27 (38)) and IEV-specific (F12 (27, 56) 77 
and A36 (57)) have been implicated in microtubule-based intracellular transport of 78 
VACV (56, 60). It was reported that A27 is required for transport of IMV to the sites 79 
of membrane wrapping where IEV are formed (40), although this was not 80 
substantiated in a later report (59). In contrast, F12 (56) and A36 (60) are involved in 81 
transport of the IEV to the cell surface and eventual egress of the virus (27, 31).  82 
 83 
Conventional kinesin is classified as a heterotetramer, which contains two heavy and 84 
two light chains (55). The light chain associates with the heavy chain through its N-85 
terminal domain while its C-terminal domain, which contains six tetratricopeptide 86 
repeat (TPR) motifs, binds to cellular cargoes (18). The motor domain present in the 87 
N-terminus of each heavy chain binds to microtubules (54). A study using a yeast 88 
two-hybrid system tested the ability of the short cytoplasmic domains of five VACV 89 
proteins (F12 (56), A36 (57), A33 (39), A34 (16) and B5 (17, 25) to bind to the TPR 90 
region of the kinesin light chain (KLC-TPR) (60). It revealed that, of the five domains 91 
tested, only the fragment from the N-terminus of A36 showed KLC-TPR-binding 92 
capability and suggested that it was a likely candidate to interact with kinesin during 93 
VACV intracellular microtubule-based transport. In other studies, it has been shown 94 
that deletion of A36 from VACV causes partial inhibition of IEV transport to the 95 
plasma membrane in infected cells (21, 22). Deletion of F12 from VACV impaired 96 
>99% of CEV formation (21). A recent study has shown that F12 has structural 97 
similarity to KLC and, as well as possessing TPR motifs, has a conserved tryptophan 98 
and aspartic acid (WD) motif essential to the binding of KLC and IEV transport (31). 99 
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A36 and E2, which have been shown to interact with F12 and to be involved in IEV 100 
transport (14, 15), were also shown to contain TPR motifs (31).  101 
 102 
Fowlpox virus (FWPV), type species of the Avipoxvirus genus, offers a safe model for 103 
investigating infection and is currently undergoing clinical trials as a non-replicating 104 
recombinant vectors for vaccination of mammals, including humans, in the fight 105 
against, malaria, HIV, avian influenza, cancer and other diseases (45). A recombinant 106 
FWPV expressing the avian influenza virus H5 hemagglutinin is probably the most 107 
extensively deployed live recombinant virus vector vaccine used in any sector, with 108 
some 2 billion doses having been used in Mexico against highly pathogenic H5N2 109 
avian influenza in poultry (8). The molecular and cell biology of FWPV have been 110 
much less extensively studied than those of VACV. In contrast to VACV, however, it 111 
has been demonstrated that production of EV of FWPV and of another Avipoxvirus, 112 
Pigeonpox virus, occurs primarily by budding of ‘naked’ IMV rather than by 113 
wrapping of IMV to produce IEV, which would in VACV in turn form EV by fusion 114 
of their outer membrane with the cell membrane (5, 19). Whether as a consequence or 115 
a cause of this strategy, it is notable that the FWPV genome (and that of the distantly 116 
related Avipoxvirus, Canarypox virus, better known as the ALVAC live recombinant 117 
vaccine vector used for many commercial veterinary vaccines and for the recent Thai 118 
HIV vaccine trial (35)) clearly lacks equivalents of a number of genes encoding 119 
proteins that play key roles in the egress of VACV and in the function of EV (2, 28, 120 
52), specifically: A27L, A33R, A36R, A56R and B5R. It retains equivalents of A34R 121 
(fpv198), E2L (fpv101), F12L (fpv109) and F13L (fpv108). Lest this might be 122 
considered a peculiarity of the Avipoxviruses, it is worth noting that this same gene 123 
spectrum is shared with the only reptilian poxvirus sequenced thus far, Crocodilepox 124 
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virus (1). Furthermore, amongst mammalian poxviruses, Parapoxviruses lack 125 
equivalents of A36R and B5R (13, 20) and Molluscum contagiosum virus lacks 126 
equivalents of A27L, B5R and E2L (43). 127 
 128 
Interaction of proteins in cells can be followed by utilizing fluorescence resonance 129 
energy transfer (FRET) between proteins pairs tagged with appropriate fluorophores, 130 
such as enhanced green fluorescent protein (EGFP) as a donor and monomeric red 131 
fluorescent protein (mDsRed) as the acceptor. The Fluorescent Lifetime Imaging 132 
Microscopy (FLIM) approach, whereby quenching of the excited state lifetime is 133 
evidence for a direct physical interaction, is an improvement over steady state FRET. 134 
This FRET-FLIM technique is highly sensitive and the change in the excited state 135 
lifetime of the donor fluorophore is concentration independent (58) and does not 136 
suffer from fluorophore bleed through. So far it has only been employed in a few 137 
studies of the interaction of viral proteins in live cells (42, 47, 48). Two photon-138 
induced FRET-FLIM (2P-FRET-FLIM) provides several advantages over the single 139 
photon method, including reduced phototoxicity (by use of near infra-red excitation 140 
light that is not absorbed by cellular components) and reduced bleaching of the 141 
fluorophore (10, 50, 51).  142 
 143 
In this study, as a positive control we have demonstrated that an interaction between 144 
full-length VACV A36, fused at its N-terminus to EGFP, and KLC-TPR, attached to 145 
mDsRed, can be observed in cells infected with Modified Vaccinia virus Ankara 146 
(MVA), using a highly sensitive FRET-FLIM technique. Infection of cells with 147 
FWPV, which does not express it own A36 ortholog, does not abrogate the interaction 148 
between the ectopically expressed VACV A36 and KLC-TPR. Furthermore, N-149 
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terminal EGFP fusions of Fpv140 (equivalent to VACV H3L) and Fpv198 (equivalent 150 
to VACV A34), could also be observed to interact with KLC-TPR-mDsRed in live, 151 
FWPV-infected cells, even though no such interactions have been reported between 152 
the equivalent VACV proteins and KLC-TPR. 153 
 154 
Materials and Methods. 155 
 156 
All reagents were purchased from Sigma UK or Invitrogen and used without further 157 
treatment unless otherwise stated.  158 
 159 
Virus and Cell culture. The origins and propagation of FWPV FP9 (FP9), as well as 160 
the isolation and purification or recombinant FWPV (rFWPV), were as described 161 
previously (4, 26, 28). 162 
 163 
Antibody. For immunofluorescence staining, the following mouse monoclonal 164 
antibodies (MAbs) were used: GB9 (anti-Fpv168), DH6 (anti-Fpv191), and DF6 165 
(anti-Fpv140), as described previously (3). Anti-beta tubulin antibody to stain 166 
microtubules was from Sigma (UK). Alexa 568 goat anti-mouse immunoglobulin G 167 
(IgG) secondary antibody was from Invitrogen (UK). 168 
 169 
Construction of plasmids. A plasmid that encodes enhanced green fluorescent protein 170 
(EGFP) was constructed in two steps. Briefly, the DNA spanning the coding sequence 171 
of EGFP was amplified from pEGFP-C1 vector (Molecular Probes) using primers, 172 
EGFP-FP (forward) and EGFP-RP (reverse) (Table 1). The amplified PCR product 173 
was gel purified (QIAGEN) for digestion with NheI and NsiI enzymes and ligated into 174 
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the XbaI and PstI sites of a FWPV expression/transfer vector, pEFGPT12S (7), under 175 
the control of an early/late synthetic poxvirus promoter. Following bacterial 176 
transformation with this intermediate plasmid, positive clones were identified by PCR 177 
and restriction enzyme analysis. DNA spanning fpv140, fpv168, fpv191 or fpv191 was 178 
amplified by PCR from FWPV FP9 genomic DNA as a template using the following 179 
primer pairs, fpv140-FP and fpv140-RP; fpv168-FP and fpv168-RP; fpv191-FP and 180 
fpv191-RP; and fpv198-FP and fpv198-RP, respectively. The resultant PCR product 181 
was gel purified (QIAGEN) and digested then ligated into SacII and XmaI sites of the 182 
generated intermediate plasmid. Similarly, transformation and subsequent 183 
identification of inserts of positive clones were performed as described above. The 184 
final recombinant plasmids were named pFPVEGFP140, pFPVEGFP168, 185 
pFPVEGFP191 and pFPVEGFP198 and they express N-terminal EGFP fusions of 186 
Fpv140, Fpv168, Fpv191 and Fpv198, respectively. 187 
 188 
A vector (pEL-KLC-TPR-mDsRed) was constructed to express kinesin light chain 189 
(KLC) tetratricopeptide repeats (TPR)-motifs containing monomeric red fluorescent 190 
protein (mDsRed) from Discosomo sp. at its N-terminus, under the control of an 191 
early/late poxvirus promoter (pEL) from, pEL-GFP-TPR plasmid (36). Briefly, the 192 
DNA corresponding to the coding sequence of mDsRed was amplified from pDsRed-193 
Monomer-C1 vector (Molecular Probes) using primers, mDsRed-FP (forward) and 194 
mDsRed-RP (reverse) (Table 1). To generate pEL-KLC-TPR-mDsRed vector, the 195 
KpnI-NotI fragment in the pEL-EGFP-TPR was replaced with the resultant PCR 196 
product, which was cut with KpnI-NotI. The pEL-GFP-TPR (36), pELA36R-EGFP 197 
(encoding Vaccinia virus A36R with C-terminal EGFP) and p-Actin-EGFP (encoding 198 
actin with N-terminal EGFP) were used for plasmid construction and protein-protein 199 
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interaction studies were a kind gift from Professor Michael Way, Cancer Research 200 
UK, London.  201 
 202 
Confocal immunofluorescence imaging. Infected or mock-infected CEFs on cover-203 
slips were prepared for immunofluorescence microscopy as described previously (3). 204 
Cells were transfected as required using Lipofectamine according to the 205 
manufacture’s recommendations (Invitrogen). Confocal fluorescence images were 206 
obtained using either a Leica TCS NT confocal microscope or a Nikon eC1 attached 207 
to a TE2000 inverted microscope with a x60 objective (Nikon, NA 1.2, water 208 
immersion). Images were processed and annotated using Photoshop, version CS4 209 
(Adobe). 210 
 211 
FRET-FLIM analysis. Protein-protein interaction analysis in live, infected/co-212 
transfected CEFs was carried out at the Central Laser Facility of the Rutherford 213 
Appleton Laboratory using a FRET-FLIM setup, as previously described (33). 214 
Briefly, multiphoton excitation was delivered from a titanium sapphire laser (Mira, 215 
Coherent UK) and a frequency doubled vanadate laser (18W) as pump laser (Coherent 216 
Lasers, UK) optimised for delivering laser light at a wavelength of 910 +/- 5 nm with 217 
180 fs pulses at 75 MHz repetition rate. The laser was focussed to generate a 218 
diffraction-limited spot through a x60 objective (Nikon, NA 1.2, water immersion) to 219 
excite specimens on the microscope stage (Nikon TE2000U). Fluorescence emission 220 
from the specimen was obtained through a band-pass filter (BG39, Comar) using a 221 
non-descanned port of the confocal microscope. Single photon pulses were detected 222 
through an external high speed microchannel plate R3809U-photomultiplier tube 223 
(Hamamatsu), and reference laser, frame sync, line sync, and pixel clock signals of 224 
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the scanning system were collected using a Time-Correlated Single Photon Counting 225 
(TCSPC) PC-module SPC830 (Becker and Hickl, Germany). 226 
 227 
Cells expressing both EGFP (488 nm excitation) and mDsRed (543 nm excitation) 228 
fusion proteins were selected following confocal microscopy. FRET-FLIM data was 229 
collected as optical Z-stacks of infected/co-transfected cells due to the diffraction 230 
limited size of the viral particles (~250 nm). Cells expressing EGFP alone were 231 
selected as a FLIM control for a non-interacting EGFP excited state lifetime. The 232 
changes in the lifetime of the EGFP, in the region of interest (the contour of 233 
individual cells), were analysed using SPCImage analysis software (Becker and Hickl, 234 
Germany) and the determined average lifetime of EGFP data was analysed by 235 
independent-samples T test using statistical analysis software, SPSS (version 17).  236 
 237 
Results 238 
 239 
Use of 2P-FRET-FLIM to demonstrate interaction between VACV A36 and KLC-240 
TPR in live cells infected with VACV MVA. The 2P-FRET-FLIM technique was 241 
employed to demonstrate the expected in vivo interaction of the EGFP-VACV A36 242 
(A36-EGFP) full length fusion with KLC-TPR-mDsRed. Live CEF cells infected with 243 
MVA and transfected with plasmid expression constructs for either A36-EGFP or 244 
Actin-EGFP alone, without KLC-TPR-mDsRed, were used to provide controls to 245 
establish the unquenched lifetime of EGFP in the context of the fusion proteins. At 24 246 
hours post-infection (h.p.i.), the average excited state fluorescence lifetime of EGFP 247 
in the A36, Actin or Fpv168 fusions, following two-photon excitation (910 nm) in the 248 
absence of KLC-TPR-mDsRed acceptor, was determined to be 2.45 + 0.1 ns (Table 249 
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2). Images of a representative control cell expressing Fpv168-EGFP, including a 250 
pseudo-colour-coded image displaying a diffraction limited resolution image of the 251 
lifetime of the Fpv168-EGFP fluorophore, are shown in Fig 1 (A to C”). The excited 252 
state lifetime of A36-EGFP in CEFs at 24 h.p.i. with MVA and transiently expressing 253 
KLC-TPR-mDsRed, reduced to an average of 2.15 + 0.14 ns (Fig. 1 F’ , Table 2), 254 
indicating that the EGFP and mDsRed moieties are located within 10 nm of each 255 
other and that A36 therefore interacts with KLC-TPR in MVA-infected CEFs, 256 
consistent with the previous yeast two-hybrid and glutathione-S-transferase (GST)-257 
pull down data (60). At higher magnification, faint puncta indicative of intracellular 258 
virions are present (panels F to E’), labelled by the A36-EGFP. The puncta are less 259 
bright than those seen in FWPV-infected cells labelled with Fpv140-EGFP (panel J’) 260 
or Fpv198-EGFP (panel S’). This may be due to low efficiency of incorporation of 261 
A36 into the MVA strain, which has not been well-studied in this regard, or a kinetic 262 
affect as MVA infection of CEFs progresses faster than FWPV infection. The 263 
locations of the puncta are compatible with areas of interaction in the cytoplasm 264 
(panels E’ and F”). 265 
 266 
2P-FRET-FLIM demonstrates that the interaction between ectopically-expressed 267 
VACV A36 and KLC-TPR is not abrogated in live cells infected with Fowlpox virus. 268 
Since interaction of VACV A36 with kinesin was detected in MVA infected cells by 269 
FRET-FLIM, we investigated whether it could also interact with KLC-TPR when 270 
expressed ectopically in cells infected with FWPV, a virus which lacks an ortholog of 271 
A36 (2, 28). At 24 h.p.i., the average fluorescence lifetime of A36-EGFP in the 272 
presence of KLC-TPR-mDsRed in FWPV-infected CEFs, was 2.2 + 0.1 ns (Fig. 1 and 273 
Table 2), comparable to the level in MVA-infected cells (2.15 + 0.14 ns) and 274 
 12 
significantly lower than the control value of 2.45 + 0.1 ns. This indicates that A36 is 275 
able to bind to KLC-TPR when expressed in cells infected with either VACV or 276 
FWPV. No puncta indicative of FWPV virions labelled with A36-EGFP were visible 277 
though there was significant interaction outside of the viral factory (panel I”). It may 278 
be that, in FWPV-infected cells, the interaction occurs only between KLC-TPR and 279 
A36 embedded in cellular, rather than viral, membranes. 280 
 281 
Expression and localization of EGFP-fusions of FWPV structural proteins in live, 282 
FWPV-infected cells. Because FWPV does not encode an equivalent of VACV IEV-283 
surface protein A36, and because the IMV of FWPV are not generally wrapped to 284 
produce IEV, it is obvious that FWPV proteins other than an A36 equivalent must be 285 
responsible for recruiting kinesin so that the progeny virions, which are 286 
predominantly IMV, might be transported from the viral factory directly to the cell 287 
surface for budding. Equivalents of VACV IMV-surface protein A27, as well as IEV-288 
surface proteins A33, A56 and B5 are also not encoded. The most likely remaining 289 
candidates are the known FWPV IMV surface proteins, namely Fpv140, equivalent to 290 
VACV IMV-surface protein H3, and Fpv191, equivalent to the ‘virion occlusion 291 
protein’ encoded by p4c gene (A26L) found in VACV Western Reserve  (Joklik 292 
strain) (30). The FWPV equivalents of proteins found on the surface of VACV IEV 293 
(such as VACV A34 and F12) were considered less likely as KLC-TPR interacting 294 
partners for IMV motility but their distribution, location and topology, which have not 295 
been described in FWPV infected cells, might conceivably be different from those 296 
observed for their VACV equivalents. 297 
 298 
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EGFP-fusions of FWPV equivalents of H3, p4c, A34 and, as a likely clear negative 299 
control, IMV-core protein A4, were expressed in cells infected with rFWPV carrying 300 
the appropriate EGFP-fusion gene, as well as the parental gene expressing the 301 
respective native protein (Fpv140, Fpv191, Fpv198 and Fpv168, respectively). The 302 
locations of the expressed EGFP-fusion proteins were confirmed by confocal 303 
microscopy, using specific FWPV monoclonal antibodies for co-localisation studies. 304 
The intracellular locations of EGFP-fusions of three of these FWPV proteins (Fpv140, 305 
Fpv168 and Fpv191) in the cytoplasm at 24 h.p.i. (Fig. 2, 3 and 4) were comparable to 306 
locations of the corresponding native proteins determined by immunofluorescence 307 
microscopy using MAbs, as reported previously (3); no antibodies are available for 308 
Fpv198. In cells infected with rFWPV expressing Fpv140-EGFP, Fpv168-EGFP or 309 
Fpv198-EGFP and stained with anti-tubulin, the EGFP-fusion proteins were seen to 310 
localize to virions some of which were found to be in close proximity to microtubules 311 
(Fig. 2). At 24 h.p.i, as well as diffuse distribution throughout the cytoplasm, Fpv191-312 
EGFP showed labelling of cytoplasmic virions, which was partially coincident with 313 
labelling of virions by monoclonal antibody to Fpv191 (Fig. 2).  314 
 315 
Staining of cells infected with rFWPV expressing each of the EGFP-fusion proteins 316 
using monoclonals against the various structural proteins revealed considerable 317 
colocalization, especially on virions, indicating that the EGFP-fusion proteins 318 
functioned as expected. Fpv168-EGFP showed good, incomplete colocalization on 319 
cytoplasmic virions immunolabelled with anti-Fpv140 (Fig. 4 A) or anti-Fpv191 (Fig. 320 
4 B). Fpv191, whether as an EGFP-fusion protein or immunolabelled, displayed good, 321 
incomplete colocalization with Fpv140, immunolabelled or as an EGFP-fusion 322 
protein, on extracellular virions (Fig. 4 C and F, respectively). Fpv140 and Fpv168 323 
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did not colocalize on cytoplasmic pools whatever the route of labelling (Fig. 4 A and 324 
E), nor did Fpv191 colocalize on cytoplasmic pools with Fpv168 or Fpv140-EGFP, as 325 
an EGFP-fusion protein (Fig. 4 D) or immunolabelled (Fig. 4 F), respectively. 326 
Fpv198-EGFP showed little sign of colocalization with immunolabelled Fpv140 or 327 
Fpv191 (Fig. 4 G and I, respectively) but there was evidence of colocalization with 328 
immunolabelled Fpv168 in cytoplasmic pools (Fig. 4 H). 329 
 330 
Use of 2P-FRET-FLIM to probe interactions between EGFP-fusions of FWPV 331 
proteins and KLC-TPR-mDsRed in live, FWPV-infected cells. Having verified that 332 
the EGFP-fusions of the FWPV structural proteins behaved as expected in vivo, cells 333 
infected with rFWPV expressing each EGFP-fusion protein were transfected with 334 
KLC-TPR-mDsRed expression plasmid to permit 2P-FRET-FLIM analysis (Fig. 1, 335 
panels J to U”). By confocal microscopy, the infected cells expressing EGFP fusions 336 
of Fpv140 (L), Fpv168 (O), Fpv191 (R) and Fpv198 (U) did not show overt 337 
colocalization with mDsRed kinesin-TPR. Subsequent 2P-FRET-FLIM analysis 338 
showed that the average fluorescence lifetime of Fpv168-EGFP, in the presence of 339 
KLC-TPR-mDsRed in FWPV-infected CEFs, was 2.45 + 0.1 ns (Fig. 1 N’ to O”, 340 
Table 2), indicating the expected lack of interaction between the internal IMV core 341 
protein (equivalent to VACV A4) and KLC-TPR-mDsRed. However, the average 342 
fluorescence lifetime of Fpv140-EGFP was 2.1 + 0.15 ns, comparable to the value 343 
observed for A36-EGFP in MVA-infected cells expressing KLC-TPR-mDsRed (Fig. 344 
1 K’ to L” and Table 2), indicating an interaction between IMV surface protein 345 
Fpv140 (equivalent to VACV H3) and KLC-TPR. In contrast, Fpv191-EGFP, which, 346 
like its VACV equivalent p4c, is also found on the surface of IMV, had an average 347 
fluorescence lifetime of 2.4 + 0.1 ns (Fig. 1 Q’ to R” and Table 2), indicating that it 348 
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does not interact with KLC-TPR-mDsRed. Somewhat surprisingly, the average 349 
fluorescence lifetime for Fpv-198-EGFP was 2.08 + 0.12 ns (Fig. 1 T’ to U” and 350 
Table 2), indicating interaction between the FWPV equivalent of VACV A34 and 351 
KLC-TPR.  352 
 353 
Discussion 354 
 355 
It is likely that the absence from the FWPV genome (and from genomes of other 356 
Avipoxviruses) of a gene encoding a homologue of A36 (as well as homologues of 357 
A33, A56 and B5) is linked, either causally or consequentially, to the formation of 358 
FWPV EV by a budding rather than by a wrapping pathway. Nevertheless, FWPV 359 
virions, in the form of IMV, still need to be transported, presumably directly, from the 360 
factory to the cell membrane. Whether the mechanism for this transport, and the viral 361 
proteins required, is the same as is used to transport VACV IMV from the factory to 362 
the site of IEV formation, or is a different mechanism, is not clear. Indeed the 363 
mechanism of transport of VACV IMV has received limited attention (40, 59). 364 
 365 
The sensitivity of EGFP fused to the C-terminus of A36 (a type I glycoprotein) to 366 
quenching by mDsRed fused to KLC-TPR demonstrates that the VACV protein can 367 
be expressed in a suitable location, and in a suitable topology, for its C-terminus to 368 
interact with cytoplasmic kinesin, not only in cells infected by MVA but even in cells 369 
infected by FWPV. In VACV, the C-terminus of A36 is displayed on the cytoplasmic 370 
face of the IEV (as well as on the cytoplasmic side of the plasma membrane, under 371 
CEV). The localisation of A36-EGFP when transiently expressed in FWPV-infected 372 
cells has not been carefully investigated, though confocal imaging revealed that 373 
 16 
FWPV, like VACV, is able to recruit VACV A36-EGFP to a perinuclear region. It 374 
has been shown that, in VACV-infected cells, A36 is unable to recruit kinesin by 375 
itself and that it requires the activity of VACV F12 (31).  FWPV does express an 376 
equivalent of F12, namely Fpv109, which is presumably competent at recruiting 377 
VACV A36 to kinesin, though the nature of the structure at which the recruitment 378 
occurs is not known. 379 
 380 
The use of the highly sensitive FRET-FLIM technique was then extended to detect 381 
interactions, in rFWPV-infected live CEFs, between KLC-TPR and EGFP-tagged 382 
FWPV structural proteins. That all of these proteins are present in or on virions is 383 
indicated by colocalization of the EGFP-fusions for Fpv140, Fpv168, Fpv191 and, 384 
rarely, Fpv198 with small puncta labeled with monoclonal antibody to Fpv191 (Fig. 3 385 
and 4). 386 
 387 
As would be expected, the 39-kDa internal core protein Fpv168 (homologous to 388 
VACV A4) showed no evidence by FRET-FLIM of interacting with KLC-TPR. 389 
However, the observed interaction between Fpv140 (homologous to the VACV IMV 390 
surface protein H3) and KLC-TPR-mDsRed represents evidence of a novel interaction 391 
amongst poxviruses. Evidence that this interaction is not merely a serendipitous 392 
interaction between any protein on the IMV surface and KLC-TPR is provided by the 393 
lack of interaction observed between Fpv191 (homologous to VACV p4c) and KLC-394 
TPR. 395 
 396 
Fpv140, like its VACV homolog H3 (30 and 37 kDa), has been shown to have 397 
multiple non-glycosylated forms (30 and 35kDa) and has been identified as a 398 
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peripheral membrane protein present on the external surface of IMV particles (3). 399 
Fpv140 contains a C-terminal hydrophobic sequence, but lacks a signal sequence and 400 
the protein is expected to be incorporated post-translationally into the IMV 401 
membrane, via the C-terminal hydrophobic domain, as is the VACV H3 protein (12). 402 
Like VACV H3 (29), Fpv140 contains potential heparan sulphate binding sites (3), 403 
which in VACV allow IMV entry. However, no interaction between H3 and kinesin 404 
has been reported for VACV.  405 
 406 
The detection of an interaction between Fpv198 (homologous to VACV A34) and 407 
KLC-TPR raises the question of how such an interaction might be mediated, given the 408 
localization of VACV A34 to the IEV surface and the general lack of production of 409 
FWPV IEV. In some ways though, that interaction might be viewed as similar to the 410 
interaction observed when VACV A36-EGFP is expressed ectopically in the FWPV-411 
infected cell, as the tagged N-terminus of A34 and the tagged C-terminus of A36 are 412 
displayed on the cytoplasmic surface of VACV IEV. However the C-terminal domain 413 
of A36 is much longer than the N-terminal domain of A34. In VACV, A34 is a type II 414 
integral membrane glycoprotein found in the Golgi, on EV and on the surface of IEV. 415 
Interaction between VACV A34 and kinesin was excluded based on the evidence that 416 
the N-terminal (cytoplasmic) domain did not bind to KLC-TPR in a yeast two-hybrid 417 
system (60). It has recently been shown that migration of A34 from the Golgi is 418 
dependent on the presence of the ‘stalk’ region of B5 (6), but FWPV encodes no 419 
homolog of B5. The location of the FWPV equivalent of VACV A34, Fpv198 (which 420 
shares only 31% amino acid identity with A34), has not been characterised but the 421 
morphogenesis of FWPV primarily by IMV budding means that it might be 422 
considered surprising for Fpv198-EGFP to be found on cytoplasmic IEV, unless they 423 
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represent a minority population of intracellular virions. It would be less surprising for 424 
Fpv198 to traffic on cellular vesicles, displaying the same topology as in VACV IEV, 425 
to the cell surface, where it might be acquired as an EV protein by budding FWPV 426 
IMV, though the EV surface proteins of FWPV have not yet been defined. Confocal 427 
imaging shows rare virions (it is not clear whether these are intra- or extra-cellular), 428 
which are labelled for DNA and immuno-labelled for Fpv191 (p4c equivalent), also 429 
displaying Fpv198-EGFP. It is even remotely conceivable that, in FWPV, Fpv198 430 
might represent an IMV surface protein, transferred from the endoplasmic reticulum 431 
to IMV with retention of topology, as has been observed for VACV A9 (24). 432 
 433 
Fpv191 (63-kDa) is a member of the A-type inclusion (ATI)-like protein family. 434 
However, the protein has been shown to be present in IMV and EV but, unlike 435 
Fpv140, Fpv168 and Fpv198, the protein does not colocalize with viral factories in 436 
FWPV-infected cells (3). The origins, nature and relationships of this protein and its 437 
orthologs have been considered in considerable detail elsewhere (3, 30). The manner 438 
of association of Fpv191 with FWPV IMV is unclear but is probably equivalent to the 439 
IMV association of VACV proteins p4c and A27 (as they do not colocalize with virus 440 
factories but bind after formation of IMV (41, 44, 49), involving protein-protein 441 
interactions with other VACV IMV membrane proteins, such as A17 (23)). It was 442 
suggested that VACV A26 (p4c) might act as a regulator to suppress formation of EV 443 
in favour of IMV production (53). It is possible, therefore, that Fpv191 (and possibly 444 
p4c) might be involved in disrupting the interaction of membrane-bound IMV with 445 
KLC-TPR (though ATI-bound IMV might require an alternative transport 446 
mechanism). 447 
 448 
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The observation of interactions between Fpv140 and KLC-TPR and between Fpv198 449 
and KLC-TPR raises the question of the nature of the molecular determinants for 450 
those interactions. Recent analysis of VACV F12 revealed the presence of 451 
tetraticopeptide repeats (TPRs) and structural similarity between the TPR domain of 452 
F12 and that of KLC (31). The same authors also report the presence in VACV A36 453 
and E2 of TPRs. Fpv140 also shows the presence of repeats with some similarity to 454 
TPRs (Gareth Morgan, personal communication), which could account for the 455 
observed interaction with KLC-TPR in FWPV-infected cells.  456 
 457 
It is much more difficult to account for the observed interaction between Fpv198 and 458 
KLC-TPR, particularly if Fpv198 displays the same topology and similar localization 459 
in FWPV-infected cells as does A34 in VACV-infected cells. In that case, Fpv198 460 
would only display a short N-terminal cytoplasmic sequence (the location of the 461 
EGFP tag) of 13 amino acids for interaction with KLC-TPR. It is possible that 462 
localization of TPR to this domain is mediated by another FWPV protein with a 463 
longer cytoplasmic domain, this protein interacting with the longer domain of Fpv198 464 
in the lumenal compartment. Resolution of this issue will no doubt require further 465 
investigation into the localization and topology of Fpv198 in FWPV-infected cells.  466 
 467 
In conclusion, using the highly sensitive time resolved FRET-FLIM imaging 468 
technique, this study has demonstrated that Fpv140 and Fpv198 interact with KLC-469 
TPR in FWPV infected cells. VACV A36 and Fpv168 served as positive and negative 470 
controls, respectively. The Fpv198 interaction may represent interaction of a rare 471 
population of FWPV IEV with kinesin, though it might represent interaction of host 472 
cell transport vesicles with kinesin. The Fpv140 interaction, a novel interaction 473 
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amongst poxviruses, probably represents interaction between FWPV IMV and 474 
kinesin, allowing transport directly from the viral factory to the cell membrane for 475 
budding. Although it is an intriguing possibility that the VACV ortholog, H3, might 476 
similarly interact with KLC-TPR, the divergence in sequence (FWPV and VACV 477 
orthologs share only 31% amino acid identity) and morphogenesis (budding versus 478 
wrapping) indicates that this is by no means a foregone conclusion. The lack of 479 
interaction for Fpv191 demonstrates that not all IMV proteins interact with KLC-480 
TPR, and might even indicate a regulatory role for Fpv191, as has been suggested for 481 
VACV p4c. 482 
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Table 1. Gene specific primers used for constructing recombinant plasmids 686 
 687 
Gene Primer name Primer sequence (5’-3’) 
egfp EGFP-FP AGATCCGCTAGCGCTACC 
 EGFP-RP CCATGCATCAGCCCGGGTCCGCGGCcagatcttcttcagaaataagtttttgttcC
TTGTACAGCTCGTCCATGC 
   dsRed mDsRed-FP GGGGTACCAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAA
ATAAG ACCATGGACAACACCGAGGACG 
 mDsRed-RP GGGGGCGGCCGCCctgggagccggagtggcggg 
fpv140 fpv140-FP CCCCCCGCGGCGCCGGGCGACAAGAAAC 
 fpv140-RP CCCCCGGGCATAGAATACGCTAAAAATACTCCAG 
   fpv168 fpv168-FP CCCCCCGCGGAGAACTTCCACAAAGATTTTATTTCTAGAATC 
 fpv168-RP CCCCCGGGAGGAATAATAGCATCTCTGAGTTCTC 
   fpv191 fpv191-FP CCCCCCGCGGATGTTGTTCCTGGAGCCGG 
 fpv191-RP CCCCCGGGTTCCATGTATAGATGGCCATATCC 
   fpv198 fpv198-FP CCCCCCGCGGCGAATAGACAAAGCAGTGAGAAAC 
 fpv198-RP CCCCCGGGGAAAAATGGACTAAAGCAAATTCCC 
 688 
 689 
 690 
Table 2: Analysis of Fluorescence Resonance Energy Transfer-Fluorescence Lifetime 691 
Imaging Microscopy data of Fowlpox virus protein interactions with kinesin 692 
 693 
Virus Donor Acceptor Lifetime 
(nanoseconds) 
Mean ± s.d. 
Significance 
(P-value) 
FWPV or 
MVA  
Actin-EGFP or A36R-EGFP 
or Fpv168-EGFP 
None 2.45±0.1 
 
 
MVA A36R-EGFP KLC-TPR-mDsRed 2.15±0.14 0.0 
FWPV  A36R-EGFP KLC-TPR-mDsRed 2.20±0.1 1.58x10-7 
rFWPV Fpv140-EGFP (VV H3) KLC-TPR-mDsRed 2.1±0.15 2.97x10-7 
rFWPV Fpv168-EGFP (VV A4) KLC-TPR-mDsRed 2.45±0.1 0.964 
rFWPV Fpv191-EGFP (VV p4c) KLC-TPR-mDsRed 2.4±0.1 0.327   
rFWPV Fpv198-EGFP (VV A34) KLC-TPR-mDsRed 2.08±0.12 1.37x10-7 
 694 
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Figure 1. 696 
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Figure 2. 701 
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Figure 3. 722 
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Figure 4.  731 
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 734 
736 
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Table legends. 737 
 738 
Table 1. Fowlpox virus (FWPV), egfp and dsRed gene-specific forward (FP) and 739 
reverse (RP) primers were designed based on sequences of the FWPV genome, 740 
pEGFP-C1 (Clontech) and pDsRed-Monomer-C1 (Clontech), respectively. 741 
Restriction sites: NheI (single underlined), NsiI (single dotted line), XmaI (double 742 
lined), SacII (wavy lined), KpnI (boxed), and NotI (light shaded); a Myc tag coding 743 
sequence (lower case), the synthetic Vaccinia virus early/late promoter (dark shade), 744 
the complement of sequence encoding the C-terminus of the egfp gene (double wavey 745 
line) plus the N-terminus (bold) and the C-terminus (lower case, italicised) of the 746 
dsRed gene are indicated in the primer sequence.  747 
 748 
Table 2. Chicken embryo fibroblasts-infected with Modified Vaccinia virus Ankara 749 
(MVA; positive control) or parental Fowlpox virus (FWPV FP9 strain) or 750 
recombinant FWPV FP9 expressing FWPV EGFP fusion proteins (Vaccinia virus 751 
orthologs in brackets) were transfected either with plasmids expressing Actin-EGFP 752 
or KLC-TPR-mDsRed; or cotransfected with two plasmids, one expressing Vaccinia 753 
virus A36R-EGFP and the other expressing KLC-TPR-mDsRed. Fluorescence 754 
Resonance Energy Transfer-Fluorescence Lifetime Microscopy data were collected at 755 
24-hour post infection/transfection and analyzed statistically using two-tailed 756 
Student’s t test. Acceptor refers to co-transfection, or not, of plasmid expressing 757 
KLC-TPR-mDsRed. s.d. is standard deviation. N=5 infected cells. 758 
 759 
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Figure Legends. 760 
 761 
Figure 1. Confocal laser scanning microscopy (CLSM) and Fluorescence Resonance 762 
Energy Transfer (FRET)-Fluorescence Lifetime Imaging Microscopy (FLIM) analysis 763 
of transfected and/or poxvirus-infected live chicken embryo fibroblasts, at 24-hour 764 
post infection. Panels A to C” are only infected (with recombinant Fowlpox virus, 765 
FWPV, rfpv168-EGFP), to show expression of fusion protein Fpv168-EGFP alone as 766 
a representative, unquenched, negative control. Panels D to I” are transfected with 767 
plasmids expressing A36-EGFP and KLC-TPR-mDsRed, and infected with Modified 768 
Vaccinia virus Ankara (MVA; panels D to F”) or parental Fowlpox virus (FWPV FP9 769 
strain; panels G to I”). MVA- and FP9-infected cells show colocalization (F and I, 770 
respectively) and interaction (E’ to F” and H’ to I”, respectively) of VACV A36 with 771 
kinesin-TPR. Panels J to U” are transfected with plasmid expressing KLC-TPR-772 
mDsRed, and infected with recombinant FWPV expressing: Fpv140-EGFP (rfpv140-773 
EGFP; panels J to L”), Fpv168-EGFP (rfpv168-EGFP; panels M to O”), Fpv191-774 
EGFP (rfpv191-EGFP; panels P to R”) or Fpv198-EGFP (rfpv198-EGFP; panels S to 775 
U”). Colour-coded excited lifetimes of EGFP are shown in panels: C’, F’, I’, L’, O’, 776 
R’ & U’. Panels: C”, F”, I”, L”, O”, R” & U” show areas of strong interaction (Red 777 
shades) and non-interaction (Blue shades). The distribution curves indicate the 778 
relative occurrence frequency of the lifetimes within the lifetime image. The 779 
distribution curves in L’ and U’ describe a steep distribution of maximum EGFP only 780 
lifetime observed at ~2.5 ns, while lower values for interaction spread from 1.6 to 2.2 781 
ns. Yellow shades in CLSM images indicate colocalization. To highlight interacting 782 
(Red shades) and non-interacting (Blue shades) areas in the colour-coded image, the 783 
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green channel was switched off and the intensity level was adjusted using Adobe 784 
Photoshop (CS4 version). Scale bar, 10 µm. 785 
 786 
Figure 2. Localisation of three of the EGFP-tagged FWPV proteins to Fowlpox virus 787 
(FWPV) virions in close proximity to microtubules in recombinant FWPV FP9-788 
infected chicken embryo fibroblast cells. Cells infected with individual recombinant 789 
FWPVs expressing one of the EGFP fusions (Green) of FWPV proteins Fpv140-790 
EGFP (A and B); Fpv168-EGFP (C and D) or Fpv198-EGFP (E to H) were stained, at 791 
24 h.p.i. for microtubules (using mouse anti-tubulin antibody/Alexa 568 goat anti-792 
mouse immunoglobulin G (IgG) (Red)) and DNA (with ToPro-3 (Blue)). Merged 793 
channels are shown in panels A, C and E; zoomed sections of merged green and red 794 
channels are shown in panels B, D and F to H. Solid arrows indicate virus particles. 795 
Scale bar, 10 µm. 796 
 797 
Figure 3. Recognition of EGFP fusion of Fowlpox virus (FWPV) protein Fpv191-798 
EGFP by monoclonal antibody raised against native protein Fpv191. A cell infected 799 
with recombinant FWPV (A to D) expressing both parental Fpv191 and Fpv191-800 
EGFP (Green), stained (Red) using anti-Fpv191 monoclonal antibody (mDH6) and 801 
Alexa 568 goat anti-mouse immunoglobulin G (IgG), analyzed by 802 
immunofluorescence microscopy, at 24 hour post infection. Colocalization is 803 
incomplete; solid arrows indicate incidences of colocalization compatible with 804 
virions. DNA staining (Blue; labelled with ToPRO-3) reveals the location of the viral 805 
factories (indicated by open arrows). Scale bar, 10 µm. 806 
 807 
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Figure 4. Colocalization of Fowlpox virus (FWPV) EGFP-fusion proteins with 808 
FWPV structural proteins recognised by monoclonal antibodies (MAb). Chicken 809 
embryo fibroblasts infected with recombinant FWPV FP9 (rFWPV) expressing the 810 
native structural proteins and one of the EGFP-fusion proteins (Green): Fpv140-EGFP 811 
(E, F), Fpv168-EGFP (A, B), Fpv191-EGFP (C, D) and Fpv198-EGFP (G, H, I), were 812 
immunolabelled at 24 h.p.i. with: anti-Fpv140 (MAb DF6; A, C, G), anti-Fpv168 813 
(MAb GB9; D, E, H) or anti-Fpv191 (MAb DH6; B, F I) antibody. DNA was labelled 814 
with ToPRO-3 (Blue; G, H). Merged images are shown, as are zoomed green/red 815 
merged channels.  Yellow shades indicate colocalization of EGFP-fusion proteins 816 
with immunolabelled proteins. Scale bar, 10 µm. 817 




Figure 1. Confocal laser scanning microscopy (CLSM) and Fluorescence Resonance 
Energy Transfer (FRET)-Fluorescence Lifetime Imaging Microscopy (FLIM) analysis 
of transfected and/or poxvirus-infected live chicken embryo fibroblasts, at 24-hour 
post infection. Panels A to C” are only infected (with recombinant Fowlpox virus, 
FWPV, rfpv168-EGFP), to show expression of fusion protein Fpv168-EGFP alone as 
a representative, unquenched, negative control. Panels D to I” are transfected with 
plasmids expressing A36-EGFP and KLC-TPR-mDsRed, and infected with Modified 
Vaccinia virus Ankara (MVA; panels D to F”) or parental Fowlpox virus (FWPV FP9 
strain; panels G to I”). MVA- and FP9-infected cells show colocalization (F and I, 
respectively) and interaction (E’ to F” and H’ to I”, respectively) of VACV A36 with 
kinesin-TPR. Panels J to U” are transfected with plasmid expressing KLC-TPR-
mDsRed, and infected with recombinant FWPV expressing: Fpv140-EGFP (rfpv140-
EGFP; panels J to L”), Fpv168-EGFP (rfpv168-EGFP; panels M to O”), Fpv191-
EGFP (rfpv191-EGFP; panels P to R”) or Fpv198-EGFP (rfpv198-EGFP; panels S to 
U”). Colour-coded excited lifetimes of EGFP are shown in panels: C’, F’, I’, L’, O’, 
R’ & U’. Panels: C”, F”, I”, L”, O”, R” & U” show areas of strong interaction (Red 
shades) and non-interaction (Blue shades). The distribution curves indicate the 
relative occurrence frequency of the lifetimes within the lifetime image. The 
distribution curves in L’ and U’ describe a steep distribution of maximum EGFP only 
lifetime observed at ~2.5 ns, while lower values for interaction spread from 1.6 to 2.2 
ns. Yellow shades in CLSM images indicate colocalization. To highlight interacting 
(Red shades) and non-interacting (Blue shades) areas in the colour-coded image, the 
green channel was switched off and the intensity level was adjusted using Adobe 
Photoshop (CS4 version). Scale bar, 10 µm. 
 
Figure 2. Localisation of three of the EGFP-tagged FWPV proteins to Fowlpox virus 
(FWPV) virions in close proximity to microtubules in recombinant FWPV FP9-
infected chicken embryo fibroblast cells. Cells infected with individual recombinant 
FWPVs expressing one of the EGFP fusions (Green) of FWPV proteins Fpv140-
EGFP (A and B); Fpv168-EGFP (C and D) or Fpv198-EGFP (E to H) were stained, at 
24 h.p.i. for microtubules (using mouse anti-tubulin antibody/Alexa 568 goat anti-
mouse immunoglobulin G (IgG) (Red)) and DNA (with ToPro-3 (Blue)). Merged 
channels are shown in panels A, C and E; zoomed sections of merged green and red 
channels are shown in panels B, D and F to H. Solid arrows indicate virus particles. 
Scale bar, 10 µm. 
 
Figure 3. Recognition of EGFP fusion of Fowlpox virus (FWPV) protein Fpv191-
EGFP by monoclonal antibody raised against native protein Fpv191. A cell infected 
with recombinant FWPV (A to D) expressing both parental Fpv191 and Fpv191-
EGFP (Green), stained (Red) using anti-Fpv191 monoclonal antibody (mDH6) and 
Alexa 568 goat anti-mouse immunoglobulin G (IgG), analyzed by 
immunofluorescence microscopy, at 24 hour post infection. Colocalization is 
incomplete; solid arrows indicate incidences of colocalization compatible with 
virions. DNA staining (Blue; labelled with ToPRO-3) reveals the location of the viral 
factories (indicated by open arrows). Scale bar, 10 µm. 
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Figure 4. Colocalization of Fowlpox virus (FWPV) EGFP-fusion proteins with 1 
FWPV structural proteins recognised by monoclonal antibodies (MAb). Chicken 2 
embryo fibroblasts infected with recombinant FWPV FP9 (rFWPV) expressing the 3 
native structural proteins and one of the EGFP-fusion proteins (Green): Fpv140-EGFP 4 
(E, F), Fpv168-EGFP (A, B), Fpv191-EGFP (C, D) and Fpv198-EGFP (G, H, I), were 5 
immunolabelled at 24 h.p.i. with: anti-Fpv140 (MAb DF6; A, C, G), anti-Fpv168 6 
(MAb GB9; D, E, H) or anti-Fpv191 (MAb DH6; B, F I) antibody. DNA was labelled 7 
with ToPRO-3 (Blue; G, H). Merged images are shown, as are zoomed green/red 8 
merged channels.  Yellow shades indicate colocalization of EGFP-fusion proteins 9 
with immunolabelled proteins. Scale bar, 10 µm. 10 
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